1	Title
2	
3	Full title:
4	Antimicrobial use in laboratory rodent facilities in Australia and New Zealand- a cross-sectional
5	survey of veterinarians and facility managers
6	
7	Short title:
8	Use of antimicrobials in laboratory rats and mice in Australia and New Zealand
9	
10	Authors:
l1	Rebbecca S. Wilcox, Marc S. Marenda, Joanne M. Devlin# and Colin R. Wilks#
12	#These authors contributed equally
13	Affiliations
L4	Rebbecca S. Wilcox
L5	<b>Roles:</b> Conceptualisation, Formal analysis, Investigation, Methodology, Writing – original draft,
L6	Visualization, Corresponding author: rebbecca.wilcox@rmit.edu.au
L7	
L8	Affiliations: Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of
L9	Science, The University of Melbourne, Parkville, Victoria, 3010, Australia
20	ORCID iD 0009-0004-9853-746X
21	
22	Joanne M. Devlin
)2	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24	<b>Roles:</b> Formal analysis, Supervision, Writing – review & editing, Funding Acquisition
25	Affiliations: Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of
26	Science, The University of Melbourne, Parkville, Victoria, 3010, Australia,
27	ORCID iD 0000-0003-0400-9670
28	
29	Marc S. Marenda
30	
31	<b>Roles:</b> Formal analysis, Supervision, Writing – review & editing
32	Affiliations: Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of
33	Science, The University of Melbourne, Werribee, Victoria, 3030, Australia
34	ORCID iD: 0000-0001-6778-1110
35	
36	Colin R. Wilks
37	
38	<b>Roles:</b> Formal analysis, Supervision, Writing – review & editing
39	Affiliations: Asia Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of
40	Science, The University of Melbourne, Parkville, Victoria, 3010, Australia
41	
42	Conflicts of Interest:
43	The authors declare no conflicts of interest.
44	
45	Funding:
46	Rebbecca S. Wilcox is funded by a University of Melbourne Research Training Program Scholarship

Abstract This cross-sectional study surveyed veterinarians and facility managers to characterise the use of antimicrobials in laboratory rodent facilities within Australia and New Zealand. Most facilities (71%) reported routine administration of antimicrobials. The indications for antibiotic use reflected those described in publications and differed significantly to reasons for use in non-laboratory animals. Antimicrobials used include those of critical importance to human health, and access to these drugs is unregulated, as prescription-only classes are ordered through research catalogues, without human or veterinary physician prescriptions. The ways in which antimicrobials are used in Australian and New Zealand rodent facilities are likely contributing to antimicrobial resistance within rodent populations, particularly as they are largely administered in drinking water, risking subtherapeutic dosing. Much antimicrobial use reported is unnecessary and could be replaced with changes to husbandry and handling. The generation of resistance in both pathogenic and commensal microbes may also represent a work health and safety issue for humans working with these animals. Reported disposal of antimicrobials included discharge into wastewater, without inactivation, and some respondents reported disposal of substrate, or soiled bedding, nesting material, and disposable enrichment items, from treated animals and medicated feed into landfill, without prior inactivation. Environmental contamination with resistant microbes and antimicrobials is a significant driver of antimicrobial resistance. As such, significant opportunities exist to implement judicious and responsible use of antimicrobials within research rodent facilities in Australia and New Zealand, with a particular focus on instituting aseptic surgery, optimising dosing regimens, and inactivation of

#### Introduction

medicated water and substrate before disposal.

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Antimicrobial drug resistance (AMR) is a public health emergency and existential threat to the advances in modern medicine of the last 80 years. AMR presently accounts for over seven million deaths annually and is projected to cause ten million deaths by the year 2050 [1 - 3]. Bacterial resistance to antibiotics is inevitable, both spontaneously in nature, and in response to exposure to antimicrobials. Resistance develops when microbes undergo mutation or exchange resistance genes and is accelerated in the presence of antimicrobials [4]. To slow AMR, selective pressures must be minimised through judicious use of antimicrobials [5]. Importantly, the pipeline for new antimicrobials is slow and has been unfruitful, due to stringent regulatory requirements and low investment returns for pharmaceutical companies. Effective new antimicrobials are used for short durations when compared with drugs for other conditions, and the restricted use of newly approved antimicrobials further reduces the market share for investing companies, along with the inevitable decline in their efficacy and value when AMR develops [6]. A comprehensive 'One Health' approach is essential for successful prevention and management of numerous infectious diseases, including those caused by emerging pathogens and those due to AMR [7, 8]. AMR has been described as the 'quintessential One Health issue' [9]. A One Health approach is essential to addressing AMR, given many human antimicrobials are also used in veterinary medicine. There is evidence that some clinically relevant resistant bacteria and/or their antimicrobial resistance genes (ARGs) readily transfer from bacteria present in animals to those in humans [10, 11]. Recent studies have shown identical AMR signatures in pathogenic Escherichia coli isolated from both humans and their companion animals, humans, and other species, and between animals and the environment [12, 13]. Decades of injudicious antimicrobial use, in human and veterinary medicine, and in agriculture have resulted in the development of extensive AMR in pathogenic and opportunistic microbes, resulting in widespread morbidity and mortality. AMR bacteria are not necessarily more virulent, however, delays

in infection control due to ineffective initial treatment and testing required to determine appropriate therapy, dramatically increases the cost of medical care, and impacts human and animal patients' health [14]. Whilst the AMR implications of antimicrobial use in agriculture, aquaculture, companion animals and equids are established and the subject of considerable quantitative and qualitative research, there is a knowledge gap with respect to antimicrobial use in laboratory animals, particularly research rodents [15-17]. This is important to understand, given the considerable number of research rodents used worldwide, estimated to exceed 120 million, and their utility in biomedical research, meaning use has only grown with time [18,19]. Resistant microbes pose significant zoonotic disease risks [20,21]. Veterinarians must consider the impacts of antimicrobial use, administering them sparingly and appropriately, to safeguard the health benefits to animals, preserve efficacy and minimise promotion of AMR [22]. This also applies to use in research animals, and likewise, must be considered by animal researchers and laboratory animal veterinarians [1]. This study aimed to investigate the use of antimicrobials in research rodent facilities in Australia and New Zealand. Based on anecdotal observations and published research protocols, the authors hypothesised that most research rodent facilities would report current antimicrobial use, with a high prevalence of in-water administration and use of fluoroguinolone, tetracycline, and sulphonamide classes. This cross-sectional study aimed to question these assumptions and characterise the means in which antimicrobial containing substrates were disposed of, including wastewater, food, and bedding. The study aimed to address the significant knowledge gap around antimicrobial use in laboratory rodents, contributing to a missing component of the One Health paradigm in addressing AMR. Prior to this survey there were no published data on the extent of antimicrobial use in rodent laboratory facilities, in Australia and New Zealand, or globally.

#### **Materials and Methods**

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

The source population comprised the 158 eligible research rodent facilities across each of the states, territories and islands of Australia and New Zealand, respectively. The total number of eligible facilities was determined using a list provided by the Australia and New Zealand Laboratory Animal Association (ANZLAA) Secretariat. The eligible respondent population comprised veterinarians and animal facility managers, working in these facilities at the time of survey publication. The study population was comprised of eligible respondents, answering the survey between February 2<sup>nd</sup>, 2020, to April 2<sup>nd</sup>, 2020. Respondents self-selected and the survey was distributed online using the Qualtrics<sup>TM</sup> survey platform, through the ANZLAA members' email list. The survey is available from the corresponding author. The survey questions covered demographic aspects of respondents and the prevalence of antimicrobial use, according to class, route and duration of administration, reasons for use and how antimicrobials are sourced and disposed of. To be confident that the proportion of respondents giving a particular answer was within a constant margin of error of 6.5% of a true prevalence of 50%, a total of ninety-four (94) completed surveys were required. Sample size calculations were conducted with finite population correction, and an assumption of 50% prevalence. Data were analysed using a live excel calculator, from The Statistical Consulting Centre, University of Melbourne, using a 95% confidence interval for a single population proportion,  $\Theta$ , with a finite population adjustment. The number of required responses was calculated using the Australian Bureau of Statistics Sample Size Calculator. Data were reported in proportions: the number of respondents selecting an answer or option were divided by the total number of respondents attempting the question. Responses of 'do not know' and unanswered questions were interpreted as missing values and were excluded from analysis. To improve interpretation, or where there was redundancy, some response categories were merged. For some complex questions, respondents provided replies in free text format.

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

The study was conducted according to the guidelines of the Declaration of Helsinki. The anonymous online survey, recruitment text and accompanying Plain Language Statement were approved by the Human Research Ethics Committee of the Faculty of Veterinary and Agricultural Science, The University of Melbourne, Ethics ID Number 1955621.1. The Ethics Committee approved 'Consent being implied', given, that to complete the survey, participants first read an Ethics approved Plain Language Statement, that explained that all participant responses were anonymous, and could not be re-identified, and that participation was voluntary. **Results** Survey Response Rate and Respondent Occupation and Location Of the source population, comprising 158 eligible rodent facilities, there was a response rate of 60% (95 respondents). Respondents were composed of 46% non-veterinarians with facility managerial roles and 51% veterinarians in non-managerial roles. Three respondents (3%) did not report their roles, though completed the survey, with other answers meeting eligibility criteria. Eighty-two percent (82%) of respondents were from Australia and 18% from New Zealand. Facility Type and Housing Eighteen percent (18%) of respondents described facilities that met multiple criteria for facility type and affiliation (Fig 1). Most respondents were from universities followed by private institutes. Approximately half were associated with a human hospital, the majority, 60%, reporting facility colocation within a human hospital. A small percentage were government facilities, or animal production facilities or vendors. **Figure 1.** Types of Facilities Identified by Respondents (n=95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

\*(TAFE - Technical and Further Education Institution) Cage systems varied, with 24% using open-top conventional caging, 31% Physical Containment Level (PC) 1, 86% PC2, and 15% PC3, and one third reported multiple caging systems, usually both conventional open-top cages, and PC1 +/- PC2. Research Disciplines Most facilities (78%) reported research across multiple disciplines, including studies in: metabolic disease (67%), neuroscience (55%), oncology (53%), cardiovascular disease (40%), the microbiome (38%), infectious disease (37%), biologics and vaccine production (27%), and breeding of rodents for commercial supply (12%). A third reported use for anatomy and physiology teaching purposes. Prevalence of Antimicrobial Use Seventy-one percent (71%) of rodent facilities reported routinely using antimicrobials, with an identical prevalence across Australian and New Zealand respondents. Facilities associated with human hospitals reported the greatest use of antimicrobials (79%), followed by 76% of university respondents. Approximately two thirds (64%) of private institutes, and those without hospital or university affiliation reported routine use. A third of the commercial animal breeding and supply facilities reported routine use. Reasons for Use Most facilities reported multiple reasons for using antimicrobials, listed in Table 1. When used to treat infections, one third of respondents (29%) reported routine use of microbial culture and antimicrobial sensitivity testing (AST) to guide therapeutic decisions.

### **Table 1.** Reasons for Use of Antimicrobials Identified by Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand

Reason for Use	Percentage of Respondents
Treating infections in individual animals	74%
Infection prevention in genetically immune- deficient rodents	58%
Prevention of infection at surgery	54%
<b>Induction of genes (tetracycline promoters)</b>	51%
Infection prevention post irradiation or chemotherapy	45%
Treatment of infections in rodent colonies	31%
Alteration of the microbiome	25%
Testing of antimicrobials	8%

#### Routes of Administration

200

201

202

203

204

205

206

207

208

209

210

211

212

213

Most respondents reported multiple routes of antimicrobial administration, most commonly in drinking water (70%), commercially formulated chow (37%) or via injection (66%). Administration via commercially formulated chow was common. The least prevalent routes were in-facility bespoke addition of antimicrobials to powdered food, and subcutaneous insertion of antimicrobial releasing devices or minipumps. See Fig 2.

**Figure 2.** Route of Administration of Antimicrobials Identified by Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand

#### Prevalence of Usage According to Antimicrobial Class

The fluoroquinolone class of antimicrobial was the most administered antimicrobial, with enrofloxacin the most prevalent specific antimicrobial used. Of the 67% of respondents administering enrofloxacin, which is light sensitive, in-water, only 48% reported covering medicated water bottles to prevent light exposure. Prevalence of antimicrobial use by class, route and duration of administration, and treatment of medicated water prior to disposal is listed in **Table 2**.

**Table 2.** Prevalence of Antimicrobial Use Reported by Respondents (n = 95) from Rodent Research Facilities In Australia and New Zealand, According to Class, Route, Duration of Treatment, and Inactivation Treatment of Medicated Water Pre-disposal

Antimicrobial	Proportion	Route of	Duration	Duration	Inactivation
Class	of Facilities	Administration	< 7 days	> 7 days	of Water
					Before
					Disposal
Fluoroquinolones	79%	Injection – 74%	63%	49%	19%
e.g., enrofloxacin		In water – 67%			
		Gavage/chow- 24%			
Tetracyclines	61%	Chow* - 52%	21%	79%	18%
e.g., doxycycline		In water – 39%			
		Injection – 18%			
Neomycin	56%	Topical – 61%	52%	48%	10%
		In water – 39%			
		Oral *– 10%			
Trimethoprim-	52%	In water – 52%	67%	50%	0
sulphonamides		Oral – 30%			
		Injection – 44%			

Amphenicols e.g.,	39%	Topical – 100%	95%	10%	N/A
chloramphenicol					
Penicillins, e.g.,	36%	In water	53%	58%	0
amoxicillin,		(amoxicillin)– 45%			
benzyl penicillin		Injection (benzyl			
		penicillin) – 75%			
Polymyxins	35%	Topical -83%	88%	35%	0
		In water – 28%			
		Injection – 11%			
Glycopeptides	13%	In water – 57%	33%	67%	33%
e.g., vancomycin		Gavage – 43%			
		Injection – 29%			
Metronidazole	19%	In water – 20%	50%	50%	
		Oral – 60%			
		Injection – 30%			
Potentiated	19%	Injection – 80%	78%	30%	0
penicillins, e.g.,		In water – 30%			
amoxicillin-		Oral – 20%			
clavulanate					
Cephalosporins,	18%	Injection (3 <sup>rd</sup>	89%	11%	N/A
e.g., cefovecin		generation) – 80%			
		Oral (1st			
		generation)– 30%			
Aminoglycosides	11%	In water – 50%	60%	40%	0
		Injection – 50%			
		Oral – 17%			

Antifungal	11%	In water – 17%	60%	40%	0
azoles, e.g.,		Oral - 17%			
itraconazole		Topical -67%			
Macrolides, e.g.,	4%	In water – 50%	0	100%	0
erythromycin		Oral – 50%			
Lincosamides,	2%	Injection – 50%	**	**	N/A
e.g., clindamycin		Oral gavage – 50%			
Amphotericin B	2%	In water – 100%	**	**	0

\*Oral refers to oral gavage, except for tetracyclines and trimethoprim sulphonamides, where it is mostly administered in commercially compounded rodent chow

\*\* not answered

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

#### Co-administration of Antimicrobials

Twenty-nine percent (29%) of respondents reported routinely co-administering multiple antimicrobials. Given the multitude of combinations, free-text responses were requested, detailing specific antimicrobial combinations. Examples of the free text responses are shown in Fig 3.

Figure 3. Free Text Responses Describing Co-Administered Antimicrobials Reported by Respondents (n = 95) from Rodent Research Facilities In Australia and New Zealand

#### Disposal of Antimicrobials

Most facilities (81%) reported disposing medicated water, untreated, down the drain or sink. Those inactivating the antimicrobials within the water reported using chemical or heat inactivation. A minority engaged specialist contractors to dispose of water containing antimicrobials, see Fig 4.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

Figure 4. Management of Water Containing Antimicrobials before Disposal, Reported by Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand For antimicrobial treated rodent carcasses and their substrate, multiple means of disposal were reported by individual facilities. Differing physical containment designations, corresponding to degrees of biosecurity, of which most respondents had two or more designations, have specific legal obligations regarding disposal, accounting for a range of disposal methods. Respondents reported disposal of treated animal carcasses as follows: autoclaving or not autoclaving carcasses followed by disposal via a medical waste contractor, 35% and 80% respectively; 4% via incineration, 2% via landfill without prior autoclaving and 2% of respondents chose not to answer. Bedding and substrate from treated animals were disposed of via a medical waste contractor (76%), sent to land fill with no autoclaving (31%), or incinerated (2%), whilst 2% preferred not to answer. Approximately one third of respondents (27%) reported disposing of medicated chow to land fill without treatment. Most respondents used multiple disposal methods including specialised contractors with or without prior autoclaving (87%) and incineration (3%) as per Fig 5. Figure 5. Methods of Disposal of Antimicrobial Containing Substrate: Medicated Animal Carcasses, their Bedding and Medicated Food According to Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand Sourcing of Antimicrobials

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

Most facilities reported sourcing antimicrobials through multiple channels, including veterinary wholesalers (93%), research chemical and reagent suppliers (41%), with a smaller number sourcing from livestock food stores and online animal supply stores (4%), private veterinarians (4%), compounding chemists (2%) and via food compounders with a veterinary script (2%), see Fig 6. **Figure 6.** Sources of Antimicrobials Identified by Respondents (n = 95) to a Survey Exploring Use of Antimicrobials in Research Rodents in Australia and New Zealand In most cases multiple persons within facilities administered antimicrobials, including animal technicians in 86% of facilities, researchers in 84%, and veterinarians in 75%. The use of prescription-only antimicrobials was authorised by veterinarians in 83% of facilities, followed by authorisation either or also via the Institutional Drugs and Poisons License Holder, (34%). In 17% of facilities, prescription antimicrobials were used without veterinary prescription or direction, whilst 6% of respondents reported that the Animal Ethics Committee (AEC) authorised their use. Standard Operating Procedures (SOPs) for Use and Disposal of Antimicrobials Over half of facilities (60%) had standardised protocols or SOPs, for the use of antimicrobials. The remaining facilities did not (34%) or chose not to answer (6%). Twenty-four percent (24%) of facilities had SOPs for disposal of antimicrobials, and 75% did not. One percent (1%) of respondents chose not to answer. **Discussion** This survey shows that a wide range of antimicrobials are used in most rodent facilities in Australia and New Zealand. They are used across a range of research types, and include several antimicrobial

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

classes, some of which are of critical importance to human health. The survey also highlights that the common routes of administration and dosing may be inappropriate, and in general, inadequate measures are taken to ensure the antimicrobials are not released in discarded solids and wastewater. Most Laboratory Rodent Facilities in Australia and New Zealand Use Antimicrobials The survey revealed a remarkable consistency of antimicrobial use in rodent facilities, across both Australian and New Zealand, with an identical prevalence of 71%. This geographic homogeneity was reflected across types of research reported, and classes of antimicrobials used. This data cannot be compared with that from other regions, as there are no similar surveys or published data, to the authors' knowledge. However, anecdotally, and as detailed in literature on laboratory animal medicine and that describing contemporary research protocols, there is significant antimicrobial use, at unquantified levels [25-27]. Antimicrobials used include those of Critical Importance to Human Health and Access is Unregulated The survey documented administration of an extensive range of antimicrobial classes which differs from that used by veterinarians in treating companion or agricultural animal species. The Australian Strategic and Technical Advisory Group on Antimicrobial Resistance (ASTAG) has rated antimicrobials used in humans, companion, and food production animals, and those used in both, according to their importance in treating infections, and the severity of consequences should resistance emerge or be amplified [49]. Antimicrobial use in the laboratory animal sector is not included within ASTAG reviews [49]. There are no regulations for use in laboratory rodents and no antimicrobials registered for rodents. All use is off label. Several antimicrobials not used routinely in veterinary medicine, including those requiring governmental authorisation in local human settings, such as vancomycin, colistin and ciprofloxacin,

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

(enrofloxacin being the veterinary drug that is metabolised to ciprofloxacin) are used commonly in laboratory rodents, in Australia and New Zealand. Vancomycin and colistin are accessed through research supply catalogues without prescription. In Australia and New Zealand, a veterinarian must prescribe Schedule 4 (prescription animal remedy) antimicrobials for companion and food animals, whereas this is not required for use in laboratory rodents [50]. Antimicrobial Use Concurs with that Described in Published Literature The reasons for antimicrobial use reported in the survey concur with published research protocols and laboratory animal literature. Infection Prophylaxis in Immune Deficient Genetically Engineered Mouse Models The survey results mirror numerous publications detailing husbandry of immune deficient colonies, with in-water administration of prophylactic antimicrobials, primarily enrofloxacin, sulphonamides, and amoxycillin-clavulanate [1, 28, 29]. In Australia and New Zealand, enrofloxacin was the most common choice, followed by trimethoprim-sulphonamide. Prophylaxis Around Time of Surgery Prophylactic use around surgery was reported commonly in the survey. Experimental surgery on rodents is seldom performed by veterinarians or human surgeons. Surgeries are mostly undertaken by researchers with little to no formal training in aseptic technique [30]. Lack of training may unnecessarily inflate rates of post-operative infections and training in aseptic technique could obviate such routine use [31, 32]. Antibiotic Induction or Silencing of Gene Expression

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

Tet-On/Tet-Off mice are a commonly used mouse model in which a gene expression system has been inserted in the mouse genome. Gene expression can be turned 'on' or 'off' with tetracyclines in a mouse's food or water. A PubMed search with the term "Tet-on and Tet-off mice," returns over sixty-four million results, the model being used abundantly in biomedical research since its introduction in 1992 [33]. Extensive use of this model in Australia and New Zealand, as reported, coincides with the global literature. Prophylaxis in Whole Body Radiation and Bone Marrow Transplantation Bone marrow transplantation is commonly performed in mice, wherein they are subjected to whole body ionising irradiation, allowing subsequent engraftment of donor bone marrow. Posttransplantation, mice are immune compromised. Radiation damages the intestinal epithelium, permitting intestinal bacteria to translocate into the bloodstream causing high morbidity and mortality. Likewise, environmental microbes and pathogens cause opportunistic infections. Oral antimicrobials prior to irradiation are used prophylactically in humans, as standard of care [34, 35]. Recent studies have demonstrated in mice that similar reductions in infection are achieved with strict asepsis and use of acidified water, rather than antimicrobials [36]. Global publications cite in-water or gavaged administration of metronidazole, neomycin, ciprofloxacin and tetracyclines as prophylaxis [36]. Whilst the survey found high prevalence of use in irradiated mice, enrofloxacin (precursor of ciprofloxacin) was used most frequently and usually administered in water or by injection, not gavage. Induction of Microbiome Dysbiosis Microbiome research, the study of the complex consortia of microorganisms, their genes, and interactions with the host is dramatically changing our understandings of medicine [37]. There is growing interest in manipulation of the microbiome in mouse models to study its effects on health and

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

Much Antibiotic is Unjustified

disease. This is mostly achieved with antimicrobials [38, 39]. A PubMed search on "microbiome models in mice, using antimicrobials" returns over five million results. Most published antibiotic-induced gut microbial imbalance or dysbiosis studies employ so-called "cocktails" comprising combinations of vancomycin, neomycin, ampicillin, metronidazole, polymyxins such as colistin sulphate, carbapenems, third generation cephalosporins and other drugs [38]. One representative example prescribes: 6-8 weeks of ampicillin plus sulbactam, vancomycin, ciprofloxacin, imipenem, and metronidazole administered ad libitum in the drinking water to mice [40]. Most studies describe in-water administration [38, 41]. The data from this survey mirror such protocols, with respondents reporting administration of at least three antimicrobials concurrently and in-water administration being most common. Management of Pathogens in Individual Rodents and Colonies Treatment of infections in individual rodents, as reported by three guarters of respondents, is expected, being commonplace in veterinary medicine. A third of respondents reported treatment of whole colony infections, which aligns with agricultural practices, such as mass in-water medication in pigs and cattle [42, 43]. Antimicrobials are frequently used to suppress clinical illness or eradicate pathogens from rodent colonies. Published protocols include elimination of *Helicobacter* spp. infection with medicated feed containing amoxicillin, clarithromycin, and metronidazole; elimination of Corynebacterium bovis in immune deficient mice with in-water amoxicillin clavulanate; enrofloxacin suppression of Rodentibacter pneumotropica infection; and reduction of colony morbidity caused by Pneumocystis spp. infection with trimethoprim/sulfamethoxazole [48].

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

This survey reports frequent prophylactic use around the time of surgery, and in immunecompromised rodent colonies. Infection can be avoided in these cases with institution of strict aseptic practice and husbandry, the latter comprising specialised handling of mice, in laminar flow cabinets with sterile gloves, and provision of sterilised food, bedding, acidified water etc. Peri-surgical administration of antimicrobials has been considered 'the single most frequently abused principle of veterinary surgery' [25]. Recent retrospective studies in laboratory rodents have found no difference in post-operative infection rates in those animals not administered prophylactic antimicrobials when there is adherence to aseptic technique [30, 51]. Literature in human medicine demonstrates that antimicrobial prophylaxis is unnecessary [52]. With exceptions, such as orthopaedic, neurological, implant and gastrointestinal surgery, surgeons are encouraged to avoid routine perioperative antibiosis [53, 54]. Opportunistic infections in immune compromised mice may be prevented with aseptic husbandry techniques, and use of sterile bedding, food, and acidified or sterilised water [36]. Routine antibiotic administration in immune deficient animals may result in superinfection, as evidenced in nude rats administered months of antimicrobials, of multiple classes, to suppress Rodentibacter infection. These rats had never tested positive to Klebsiella pneumoniae, yet this pathogen arose within the colony and was extensively drug resistant following antibiosis [55]. The Rodentibacter infection recurred once antimicrobials were discontinued. The Majority of Reported Antimicrobial Use is Delivering Subtherapeutic Doses The administration of insufficient antibiotic doses, being subtherapeutic for treating infection, induces antibiotic resistance [56]. In rodent facilities, decision on the route of administration is often influenced by labour requirements [57]. Handling of individual rodents when it is necessary to administer medications to a whole colony is time consuming, expensive and requires technical expertise and attention to aseptic husbandry [58]. Consequently, in-water administration is the commonly described route in publications and was reported by most survey respondents.

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

Such mass treatment is problematic because it cannot be assured that all animals will consume sufficient water to receive an appropriate dose of antimicrobial. Also, many antimicrobials are unstable in water, or when exposed to light, including doxycycline and enrofloxacin [59, 60]. Fewer than half of survey respondents covered water bottles containing these antimicrobials, thus reducing the delivered dose. This survey also documented a high prevalence of cefovecin administration by injection. Therapeutic plasma concentrations in mice are unachievable with cefovecin, as the drug's half-life in mice is 50 minutes, compared to 7-14 days for cats and dogs, for whom it is registered [61]. Reported Use May Represent a Risk to Human and Rodent Health Numerous studies in rodents have found emergence of resistant gut microbiota, even with a single class and dose of antimicrobial [62]. These data suggest that oral administration of antimicrobials, in laboratory rodents, have pronounced and long-standing effects on resistance gene amplification and de novo development in gut microbiota [63, 64]. Microbial cross-resistance to multiple antimicrobial classes, conferred by a common molecular mechanism, may arise following administration of a single class [65, 66]. Administration of a broad range of antibiotic classes, as reported in this survey, is likely inducing multi-species microbial crossresistance. Resistant microbes are transferred vertically, from rodent dams to offspring during parturition and nursing. Resistance selected for in the microbiota, by antimicrobial administration, may be transmitted indefinitely through generations of animals, as rodent pups acquire their microbiome from their dam and the environment [67, 68]. Mouse-adapted S. aureus has been vertically transmitted in mouse colonies for generations [69]. There are numerous examples of cross infection between methicillin resistant S. aureus (MRSA) between humans and house mice and rats, and recent documentation of cross-transmission of

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

pathogenic and multidrug resistant (MDR) resistant E. coli between humans and companion animals [70-73]. A study across German research animal facilities compared microbiome profiles from the intestines of research rodents, and the skin of personnel working with these animals. Genomic sequencing found that shed skin or dust particles carried by either animals, care takers, or scientists influenced and was shared by the gastrointestinal microbiota of research mice. This demonstrated that despite standard biosecurity engineering controls of humans wearing masks, gowns and gloves in the facility, there is a significant transfer and sharing of skin microbiota from humans to research rodents. It is plausible that the converse applies, and the rodent microbiome from the gut or skin, can transfer to humans [23, 24, 74]. Another study isolated a human strain of MDR C. difficile from an outbreak in a mouse facility, co-located with a human hospital. The authors proposed that the AMR accrued through rodent exposure to antimicrobials and horizontal gene transfer, from commensals to the Clostridia. The outbreak was facility wide, despite the work occurring in rooms with high level biosecurity [75, 76]. These examples underscore the fact that laboratory rodents and facilities may harbour dangerous microbes, functioning as a reservoir for resistant pathogens and genes. This is a particular issue in human healthcare settings, and half of survey respondents reported their co-location with human hospitals. Induction of resistance in rodent pathogens, through unnecessary and subtherapeutic dosing, will also compromise animal welfare, rendering bacterial infections more difficult to treat. These factors are important to consider given the rodent housing systems documented by respondents. Specifically, conventional open-top cages were common across all facilities, and these generate significant particulate contamination of air, which is then shared between rodent cages, and personnel working the facilities are exposed to particulates, through direct contact and inhalation. During cage washing of PC1 and PC2 cages, staff are likewise, exposed to these aerosols. Sharing of air and particulates is an established work health and safety issue in all rodent facilities below PC3 biocontainment level. Lab animal allergy is a proxy. This is a condition arising from unavoidable

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

exposure of personnel to particulate matter (rodent dander) in the air, via inhalation or direct contact, regardless of cage types and engineering controls [88]. Disposal of Antimicrobials in Laboratory Rodent Waste is Causing Environmental Contamination which may Contribute to AMR. This survey showed that antimicrobial containing water is disposed of untreated by most facilities. A third of facilities administering medicated chow dispose of it untreated, in regular municipal waste, where it may contaminate the environment and be consumed by animals. Some facility waste substrates, including bedding of antimicrobial treated animals, containing urine and faeces, also are disposed of without treatment. Such practices risk contaminating the environment with antimicrobials, and microbes that may contain ARGs. The spread of drug resistance genes has been classified as new type of environmental pollutant [77]. Microbial exposure to anthropogenic antimicrobials in wastewater, agricultural settings, or the built environment, may select for AMR in the environmental resistome, generating reservoirs of resistant pathogens and microbial reservoirs of ARGs [78, 79]. Hospital and laboratory wastewater are established contributors to AMR and release of ARGs to the environment, underscoring the need for efforts to treat water pre-disposal [80-82]. Recent reviews have identified the significant and overlooked contribution of inappropriately disposed of antimicrobials as drivers of AMR in both human and veterinary medicine [83]. Whilst there is some guidance around disposal of laboratory waste that contains antimicrobials, there are no equivalent publicly available recommendations for laboratory animal waste containing antimicrobials [84]. Antimicrobials, most commonly reported in the survey, have long-standing environmental impacts. Enrofloxacin is a stable antimicrobial pollutant with a half-life as long as 3–9 years in natural environments [85]. Tetracycline containing rodent chow, commonly used by survey respondents, is largely disposed of untreated in municipal landfill. Wild birds and rodents consuming the chow from landfill may disseminate antimicrobial resistant microbes and their ARGs to human and other animal

populations. Studies demonstrate aerosolization and dissemination of resistant microbes and ARGs during routine passage of waste through transfer stations, risking the health and safety of waste workers and people living proximal to municipal landfill [86, 87].

#### Conclusion

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

rodent research facilities, in Australia and New Zealand.

In summary, this survey characterises and quantifies, for the first time, the extent of the use of antimicrobials in research rodent facilities in Australia and New Zealand. The data align with laboratory rodent literature describing regimens and protocols for antimicrobial use within research projects. We believe this is the first published quantitative, and qualitative survey of its type, globally, characterising prevalence of use, indications for and regimens of administration, means of access, and common modes of disposal of antimicrobials, administered to laboratory rodents. The survey identified areas where antimicrobial use is not indicated, and is injudicious, as well as confirming its widespread use, inherent to rodent research models, as researchers apply published consensus antimicrobial protocols. The imprudent use reported, including commonplace subtherapeutic dosing and administration of antimicrobials of critical importance to human health, and inappropriate disposal, is likely contributing to the emergence of AMR in laboratory rodents, in the environment and potentially, in persons working with the animals. This is particularly concerning where the rodent facility is collocated with a hospital since there will be many opportunities for transfer on personnel who move between the animal facility and the hospital if inadvertent breaches of biosecurity occur. Inappropriate or imprudent use of antimicrobials also has negative implications for the research rodents, which may develop untreatable infections, as well as impacts for public health at a facility and environmental level. The survey has identified an urgent need to develop and implement evidence-based standard operating principles for responsible antimicrobial usage and disposal in

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

Infect Drug Resist [Internet]. 2020 Dec 29;13:4713-38.

Acknowledgments We would like to express our gratitude to the laboratory animal community in Australia and New Zealand, for their voluntary participation in the survey. We also wish to thank the ANZLAA Secretariat for providing the contact details of all laboratory animal facilities in these countries. We would also like to acknowledge the support provided by the Statistical Consulting Centre, The University of Melbourne, for assistance with data analysis. References 1. Narver HL, Antimicrobial stewardship in laboratory animal facilities. Journal of the American Association for Laboratory Animal Science: JAALAS [Internet]. 2017;56(1):6-10. 2. Yadav S, Kapley A. Antibiotic resistance: Global health crisis and metagenomics. Biotechnol Rep (Amst) [Internet]. 2021 Feb 23;29:e00604. 3. Tomczyk S, Taylor A, Brown A, de Kraker MEA, El-Saed A, Alshamrani M, Hendriksen RS, Jacob M, Löfmark S, Perovic O, Shetty N, Sievert D, Smith R, Stelling J, Thakur S, Vietor AC, Eckmanns T, WHO AMR Surveillance and Quality Assessment Collaborating, Centres Network. Impact of the COVID-19 pandemic on the surveillance, prevention, and control of antimicrobial resistance: A global survey. J Antimicrob Chemother [Internet]. 2021 Oct 11;76(11):3045-58. 4. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr [Internet]. 2016 Apr ;4(2): 10.1128/microbiolspec.VMBF-2015. 5. Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: Fighting antimicrobial resistance and protecting global public health.

- 6. Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how
- new antibiotics are reimbursed: Development of an insurance framework for new antibiotics based on
- a policy of risk mitigation. Health Policy [Internet]. 2017 Oct;121(10):1025-30.
- 7. Velazquez-Meza M, Galarde-López M, Carrillo-Quiróz B, Alpuche-Aranda C. Antimicrobial
- resistance: One health approach. Veterinary world [Internet]. 2022;15; 2022/03/28(3):743-9.
- 8. Guardabassi L, Butaye P, Dockrell DH, Fitzgerald JR, Kuijper EJ; ESCMID Study Group for
- Veterinary Microbiology (ESGVM). One Health: a multifaceted concept combining diverse
- approaches to prevent and control antimicrobial resistance. Clin Microbiol Infect. 2020
- 545 Dec;26(12):1604-1605. doi: 10.1016/j.cmi.2020.07.012. Epub 2020 Jul 20. PMID: 32702500.
- 9. Robinson TP, Bu DP, Carrique-Mas J, Fèvre EM, Gilbert M, Grace D, Hay SI, Jiwakanon J,
- Kakkar M, Kariuki S, Laxminarayan R, Lubroth J, Magnusson U, Thi Ngoc P, Van Boeckel TP,
- Woolhouse MEJ. Antibiotic resistance is the quintessential one health issue. Trans R Soc Trop Med
- 549 Hyg [Internet]. 2016 Jul;110(7):377-80.
- 10. Kim Y, Leung MHY, Kwok W, Fournié G, Li J, Lee PKH, Pfeiffer DU. Antibiotic resistance gene
- sharing networks and the effect of dietary nutritional content on the canine and feline gut resistome.
- Animal Microbiome [Internet]. 2020;2(1):4.
- 11. Røken M, Forfang K, Wasteson Y, Haaland AH, Eiken HG, Hagen SB, Bjelland AM.
- Antimicrobial resistance-do we share more than companionship with our dogs? J Appl Microbiol
- 555 [Internet]. 2022 Aug;133(2):1027-39.
- 12. Ogura Y, Ueda T, Nukazawa K, Hiroki H, Xie H, Arimizu Y, Hayashi T, Suzuki Y. The level of
- antimicrobial resistance of sewage isolates is higher than that of river isolates in different escherichia
- 558 coli lineages. Sci Rep [Internet]. 2020 Oct 21;10(1):17880-x.
- 559 13. Elankumaran P, Cummins ML, Browning GF, Marenda MS, Reid CJ, Djordjevic SP. Genomic
- and temporal trends in canine ExPEC reflect those of human ExPEC. Microbiol Spectr [Internet].
- 561 2022 Jun 29;10(3):e0129122,22. Epub 2022 Jun 8.

- 562 14. Dadgostar P. Antimicrobial Resistance: Implications and Costs, Infect Drug Resist, 2019 Dec
- 20;12:3903-3910. doi: 10.2147/IDR.S234610. PMID: 31908502; PMCID: PMC6929930. 563
- 15. Marta-Costa A, Miranda C, Silva V, Silva A, Martins Â, Pereira JE, Maltez L, Capita R, Alonso-564
- 565 Calleja C, Igrejas G, Poeta P. Survey of the knowledge and use of antibiotics among medical and
- veterinary health professionals and students in portugal. Int J Environ Res Public Health [Internet]. 566
- 567 2021 Mar 9;18(5):2753. doi: 10.3390/ijerph18052753.
- 16. Pleydell EJ, Souphavanh K, Hill KE, French NP, Prattley DJ. Descriptive epidemiological study 568
- of the use of antimicrobial drugs by companion animal veterinarians in new zealand. N Z Vet J 569
- 570 [Internet]. 2012 Mar;60(2):115-22.
- 571 17. Kalnins NJ, Croton C, Haworth M, Gibson J, Purcell SL, Stewart AJ. A VetCompass Australia
- study of antimicrobial use in dog-to-dog bite wounds (1998-2018). Antibiotics (Basel, Switzerland) 572
- [Internet]. 2022;11(1):55. 573
- 18. Cait J, Cait A, Scott RW, Winder CB, Mason GJ. Conventional laboratory housing increases 574
- morbidity and mortality in research rodents: Results of a meta-analysis. BMC Biol [Internet]. 2022 575
- 576 Jan 13;20(1):15-0.
- 577 19. Bryda EC. The mighty mouse: The impact of rodents on advances in biomedical research. Mo
- Med [Internet]. 2013;110(3):207-11. 578
- 579 20. Angulo FJ, Nargund VN, Chiller TC. Evidence of an association between use of anti-microbial
- agents in food animals and anti-microbial resistance among bacteria isolated from humans and the 580
- human health consequences of such resistance. J Vet Med B Infect Dis Vet Public Health. 2004 Oct-581
- Nov;51(8-9):374-9. doi: 10.1111/j.1439-0450.2004.00789.x. PMID: 15525369. 582
- 583 21. Meade E, Savage M, Slattery M, Garvey M. Investigation of Alternative Therapeutic and Biocidal
- Options to Combat Antifungal-Resistant Zoonotic Fungal Pathogens Isolated from Companion 584
- 585 Animals. [Internet].; 2021 DOI: 10.3390/idr13020034

- 586 22. Weese JS, Giguère S, Guardabassi L, Morley PS, Papich M, Ricciuto DR, Sykes JE. ACVIM
- consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet 587
- Intern Med [Internet]. 2015;29(2):487-98. 588
- 23. Raafat D, Mrochen DM, Al'Sholui F, Heuser E, Ryll R, Pritchett-Corning KR, Jacob J, Walther B, 589
- 590 Matuschka FR, Richter D, Westerhüs U, Pikula J, van den Brandt J, Nicklas W, Monecke S,
- 591 Strommenger B, van Alen S, Becker K, Ulrich RG, Holtfreter S. Molecular epidemiology of
- methicillin-susceptible and methicillin-resistant staphylococcus aureus in wild, captive and laboratory 592
- 593 rats: Effect of habitat on the nasal S. aureus population. Toxins (Basel) [Internet]. 2020 Jan
- 594 24;12(2):80. doi: 10.3390/toxins12020080.
- 595 24. Sakr A, Brégeon F, Mège J, Rolain J, Blin O. Staphylococcus aureus nasal colonization: An
- update on mechanisms, epidemiology, risk factors, and subsequent infections. Frontiers in 596
- 597 microbiology [Internet]. 2018;9:2419.
- 598 25. Morris TH. Antibiotic therapeutics in laboratory animals. Lab Anim [Internet]. 1995 Jan;29(1):16-36.
- 599 26. Burkholder T, Foltz C, Karlsson E, Linton CG, Smith JM. Health evaluation of experimental
- 600 laboratory mice. Current protocols in mouse biology [Internet]. 2012;2:145-65.
- 27. Michaud CR, Qin J, Elkins WR, Gozalo AS. Comparison of 3 topical treatments against ulcerative 601
- dermatitis in mice with a C57BL/6 background. Comp Med [Internet]. 2016;66(2):100-4. 602
- 603 28. A rvee K. Shultz LD. Brehm MA. Immunodeficient mouse model for human hematopoietic stem cell
- 604 engraftment and immune system development. Methods Mol Biol [Internet]. 2014;1185:267-78.
- 29. Pearson EC, Pugazhenthi U, Fong DL, Smith DE, Nicklawsky AG, Habenicht LM, Fink MK, 605
- 606 Leszczynski JK, Schurr MJ, Manuel CA. Metaphylactic antibiotic treatment to prevent the transmission of
- 607 corynebacterium bovis to immunocompromised mouse offspring. J Am Assoc Lab Anim Sci [Internet].
- 608 2020 Nov 1;59(6):712-8.
- 609 30. Pritchett-Corning K, Luo Y, Mulder GB, White WJ. Principles of rodent surgery for the new surgeon.
- Journal of visualized experiments: JoVE [Internet]. 2011(47):2586. 610

- 31. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and 611
- 612 heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc [Internet].
- 613 2009;4(11):1670-80.
- 32. Yaltirik M, Dedeoglu K, Bilgic B, Koray M, Ersey H, Issever H, Dulger O, Soley S, Comparison 614
- 615 of four different suture materials in soft tissues of rats. Oral Dis. 2003 Nov:9(6):284-6. doi:
- 616 10.1034/j.1601-0825.2003.00954.x. PMID: 14629327.
- 617 33. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive
- 618 promoters. Proc Natl Acad Sci U S A [Internet]. 1992 Jun 15;89(12):5547-51.
- 619 34. Seo SK, Xiao K, Huang Y, Jongwutiwes U, Chung D, Maloy M, Giralt S, Barker JN, Jakubowski AA,
- 620 Papanicolaou GA. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of
- bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution 621
- 622 study. J Infect [Internet]. 2014;69(4):341-51.
- 623 35. Guiot HF, van Furth R. Selective decontamination in bone marrow transplant recipients. Epidemiol
- 624 Infect [Internet]. 1992 Dec;109(3):349-60.
- 625 36. Duran-Struuck R, Dysko RC. Principles of bone marrow transplantation (BMT): Providing optimal
- 626 veterinary and husbandry care to irradiated mice in BMT studies. J Am Assoc Lab Anim Sci [Internet].
- 2009 Jan;48(1):11-22. 627
- 628 37. Cullen CM, Aneja KK, Beyhan S, Cho CE, Woloszynek S, Convertino M, McCoy SJ, Zhang Y,
- Anderson MZ, Alvarez-Ponce D, Smirnova E, Karstens L, Dorrestein PC, Li H, Sen Gupta A, Cheung K, 629
- 630 Powers JG, Zhao Z, Rosen GL. Emerging priorities for microbiome research. Front Microbiol [Internet].
- 631 2020 Feb 19;11:136.
- 632 38. Kennedy EA, King KY, Baldridge MT. Mouse microbiota models: Comparing germ-free mice and
- 633 antibiotics treatment as tools for modifying gut bacteria. Front Physiol [Internet]. 2018 Oct 31;9:1534.
- 634 39. Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of
- 635 intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol [Internet]. 2014;277(2):138-45.

- 636 40. Fiebiger U, Bereswill S, Heimesaat MM. Dissecting the interplay between intestinal microbiota and
- 637 host immunity in health and disease: Lessons learned from germfree and gnotobiotic animal models.
- 638 European journal of microbiology & immunology [Internet]. 2016;6(4):253-71.
- 639 41. Ericsson AC, Franklin CL, Manipulating the gut microbiota; Methods and challenges, ILAR journal
- 640 [Internet]. 2015;56(2):205-17.
- 641 42. Little S, Woodward A, Browning G, Billman-Jacobe H. In-water antibiotic dosing practices on pig
- 642 farms. Antibiotics [Internet]. 2021;10(2)
- 643 43. Cusack P. Evaluation of practices used to reduce the incidence of bovine respiratory disease in
- 644 australian feedlots (to november 2021). Aust Vet J [Internet]. 2023 Mar 30
- 44. Pearson EC, Pugazhenthi U, Fong DL, Smith DE, Nicklawsky AG, Habenicht LM, Fink MK, 645
- 646 Leszczynski JK, Schurr MJ, Manuel CA. Metaphylactic antibiotic treatment to prevent the transmission of
- 647 corynebacterium bovis to immunocompromised mouse offspring. J Am Assoc Lab Anim Sci [Internet].
- 648 2020 Nov 1;59(6):712-8.
- 649 45. Jury J, Gee LC, Delaney KH, Perdue MH, Bonner RA. Eradication of helicobacter spp. from a rat
- 650 breeding colony. Contemp Top Lab Anim Sci [Internet]. 2005 Jul;44(4):8-11.
- 651 46. Kerton A, Warden P. Review of successful treatment for helicobacter species in laboratory mice. Lab
- Anim [Internet]. 2006 Apr;40(2):115-22. 652
- 47. Towne JW, Wagner AM, Griffin KJ, Buntzman AS, Frelinger JA, Besselsen DG. Elimination of 653
- pasteurella pneumotropica from a mouse barrier facility by using a modified enrofloxacin treatment 654
- 655 regimen. Journal of the American Association for Laboratory Animal Science: JAALAS [Internet]. 2014
- 656 ;53(5):517-22.
- 657 48. Weisbroth SH. Pneumocystis: Newer knowledge about the biology of this group of organisms in
- 658 laboratory rats and mice. Lab Anim (NY) [Internet]. 2006 Oct;35(9):55-61.
- 659 49. Sri A, Bailey KE, Gilkerson JR, Browning GF, Hardefeldt LY. Attitudes towards use of high-
- 660 importance antimicrobials-A cross-sectional study of Australian veterinarians. Antibiotics (Basel)
- 661 [Internet]. 2022 Nov 10;11(11):1589. doi: 10.3390/antibiotics11111589.

- 662 50. Dyke TM. Regulation of veterinary antibiotics in Australia. Commun Dis Intell Q Rep. 2003;27
- Suppl:S6-8. PMID: 12807266. 663
- 51. Moats C, Cook K, Armantrout K, Crank H, Uttke S, Maher K, Bochart RM, Lawrence G, Axthelm 664
- MK, Smedley JV. Antimicrobial prophylaxis does not improve post-surgical outcomes in SIV/SHIV-665
- 666 uninfected or SIV/SHIV-infected macaques (macaca mulatta and macaca fascicularis) based on a
- 667 retrospective analysis. PLoS One [Internet]. 2022 Apr 20;17(4):e0266616.
- 52. Giguere, G, Walker, RD, Giguere, S, Prescott, JF, Baggot, JD, Walker, RD, Dowling, PM. 668
- 669 Antimicrobial prophylaxis for surgery. [Internet]. Ames, Iowa: Blackwell Publishing; 2006. 340 p
- 670 53. Leaper DJ, Melling AG. Antibiotic prophylaxis in clean surgery: Clean non-implant wounds. J
- 671 Chemother [Internet]. 2001 Nov;13 Spec No 1(1):96-101.
- 54. Hasan GZ, Saleh FM, Hossain MZ, Amin MR, Siddiqui TH, Islam MD, Chakraborty S, Antibiotic 672
- 673 prophylaxis is unnecessary in clean surgery. Mymensingh Med J [Internet]. 2013 Apr;22(2):342-4. 4
- 674 55. Hansen AK. Antibiotic treatment of nude rats and its impact on the aerobic bacterial flora. Lab Anim
- [Internet]. 1995 Jan;29(1):37-44. 675
- 56. Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes [Internet]. 2014;5(1):3-4. 676
- 677 57. Nunamaker EA, Artwohl JE, Anderson RJ, Fortman JD. Endpoint refinement for total body irradiation
- 678 of C57BL/6 mice. Comp Med [Internet]. 2013 Feb;63(1):22-8.
- 679 58. Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. Contemp Top Lab
- 680 Anim Sci [Internet]. 2004 Nov;43(6):42-51.
- 681 59. Redelsperger IM, Taldone T, Riedel ER, Lepherd ML, Lipman NS, Wolf FR. Stability of Doxycycline
- 682 in Feed and Water and Minimal Effective Doses in Tetracycline-Inducible Systems. J Am Assoc Lab
- 683 Anim Sci. 2016;55(4):467-74. PMID: 27423155; PMCID: PMC4943619.
- 684 60. Marx JO, Vudathala D, Murphy L, Rankin S, Hankenson FC. Antibiotic administration in the drinking
- water of mice. J Am Assoc Lab Anim Sci [Internet]. 2014 May;53(3):301-6. 685

- 686 61. Sanders KL, Bas E, Cox SK, Rothen DE. Pharmacokinetics of single-bolus subcutaneous cefovecin in
- 687 C57BL/6 mice. Journal of the American Association for Laboratory Animal Science: JAALAS [Internet].
- 688 2017;56(5):558-61.
- 689 62. Korry BJ, Cabral DJ, Belenky P. Metatranscriptomics reveals antibiotic-induced resistance gene
- 690 expression in the murine gut microbiota. Frontiers in microbiology [Internet]. 2020;11:322.
- 691 63. de Nies L, Busi SB, Tsenkova M, Halder R, Letellier E, Wilmes P. Evolution of the murine gut
- 692 resistome following broad-spectrum antibiotic treatment. Nature Communications [Internet]. 2022;13(1)
- 693 :2296.
- 694 64. Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly
- 695 influence the levels of antibiotic resistance in gut microbiota. Antimicrob Agents Chemother [Internet].
- 696 2013 Aug;57(8):3659-66.
- 697 65. Colclough A, Corander J, Sheppard SK, Bayliss SC, Vos M. Patterns of cross-resistance and collateral
- 698 sensitivity between clinical antibiotics and natural antimicrobials. Evolutionary applications [Internet].
- 699 2019;12(5):878-87.
- 700 66. Shu C, Chen W, Chang Y, Chen J, Liu F, Huang Y, You C, Wu EH. Exposure to one antibiotic leads
- 701 to acquisition of resistance to another antibiotic via quorum sensing mechanisms. Frontiers in
- 702 Microbiology [Internet]. 2021;11
- 703 67. Klassert TE, Zubiria-Barrera C, Kankel S, Stock M, Neubert R, Lorenzo-Diaz F, Doehring N, Driesch
- 704 D. Fischer D. Slevogt H. Early bacterial colonization and antibiotic resistance gene acquisition in
- 705 newborns. Front Cell Infect Microbiol [Internet]. 2020 Jul 10;10:332.
- 706 68. Patangia DV, Ryan CA, Dempsey E, Stanton C, Ross RP. Vertical transfer of antibiotics and antibiotic
- 707 resistant strains across the mother/baby axis. Trends Microbiol [Internet]. 2022;30(1):47-56.
- 708 69. Schulz D, Grumann D, Trübe P, Pritchett-Corning K, Johnson S, Reppschläger K, Gumz J,
- 709 Sundaramoorthy N, Michalik S, Berg S, van den Brandt J, Fister R, Monecke S, Uy B, Schmidt F, Bröker
- 710 B,M., Wiles S, Holtfreter S. Laboratory mice are frequently colonized with staphylococcus aureus and

- 711 mount a systemic immune response-note of caution for in vivo infection experiments. Frontiers in cellular
- 712 and infection microbiology [Internet]. 2017;7:152
- 70. Gwenzi W, Chaukura N, Muisa-Zikali N, Teta C, Musyuugwa T, Rzymski P, Abia ALK. Insects, 713
- 714 rodents, and pets as reservoirs, vectors, and sentinels of antimicrobial resistance. Antibiotics (Basel,
- 715 Switzerland) [Internet]. 2021;10(1):68.
- 716 71. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant bacteria. J
- 717 Antimicrob Chemother [Internet]. 2004 Aug;54(2):321-32.
- 72. Argudín MA. Deplano A. Meghraoui A. Dodémont M. Heinrichs A. Denis O. Nonhoff C. Roisin S. 718
- 719 Bacteria from animals as a pool of antimicrobial resistance genes. Antibiotics [Internet]. 2017;6(2)
- 720 73. Pomba C, Rantala M, Greko C, Baptiste KE, Catry B, van Duijkeren E, Mateus A, Moreno MA,
- 721 Pyörälä S, Ružauskas M, Sanders P, Teale C, Threlfall EJ, Kunsagi Z, Torren-Edo J, Jukes H, Törneke K.
- 722 Public health risk of antimicrobial resistance transfer from companion animals. J Antimicrob Chemother
- 723 [Internet]. 2017 Apr 1;72(4):957-68.
- 724 74. Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, Gläsner J, Gopalakrishnan S, Grassl GA,
- Günther C, Haller D, Hirose M, Ibrahim S, Loh G, Mattner J, Nagel S, Pabst O, Schmidt F, Siegmund B, 725
- Strowig T, Volynets V, Wirtz S, Zeissig S, Zeissig Y, Bleich A, Baines JF. Analysis of factors contributing 726
- 727 to variation in the C57BL/6J fecal microbiota across german animal facilities. Int J Med Microbiol
- 728 [Internet]. 2016 Aug;306(5):343-55.
- 729 75. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. Critical role for MyD88-mediated neutrophil
- 730 recruitment during clostridium difficile colitis. Infect Immun [Internet]. 2012;80(9):2989-96.
- 731 76. Ma KGL, Lertpiriyapong K, Piersigilli A, Dobtsis I, Wipf JRK, Littmann ER, Leiner I, Pamer EG,
- Ricart Arbona RJ, Lipman NS. Outbreaks of typhlocolitis caused by hypervirulent group ST1 732
- 733 clostridioides difficile in highly immunocompromised strains of mice. Comp Med [Internet]. 2020 Jun
- 734 1;70(3):277-90.

- 735 77. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the
- new delhi environment and its implications for human health: An environmental point prevalence study.
- 737 Lancet Infect Dis [Internet]. 2011 May;11(5):355-62.
- 738 78. Finley RL, Collignon P, Larsson DGJ, McEwen SA, Li X, Gaze WH, Reid-Smith R, Timinouni M,
- 739 Graham DW, Topp E. The scourge of antibiotic resistance: The important role of the environment. Clin
- 740 Infect Dis [Internet]. 2013 Sep;57(5):704-10.
- 79. Wellington EMH, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, Johnson-Rollings AS, Jones
- DL, Lee NM, Otten W, Thomas CM, Williams AP. The role of the natural environment in the emergence
- of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis [Internet]. 2013 Feb;13(2):155-65.
- 744 80. Fouz N, Pangesti KNA, Yasir M, Al-Malki A, Azhar EI, Hill-Cawthorne G, Abd El Ghany M. The
- 745 contribution of wastewater to the transmission of antimicrobial resistance in the environment: Implications
- of mass gathering settings. Tropical medicine and infectious disease [Internet]. 2020;5(1):33.
- 747 81. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential
- 748 resistance in environmental sources; Potential public health implications. Molecules [Internet]. 2018 Mar
- 749 30;23(4):795. doi: 10.3390/molecules23040795.
- 750 82. Paulus GK, Hornstra LM, Alygizakis N, Slobodnik J, Thomaidis N, Medema G. The impact of on-site
- hospital wastewater treatment on the downstream communal wastewater system in terms of antibiotics and
- antibiotic resistance genes. Int J Hyg Environ Health [Internet]. 2019;222(4):635-44.
- 753 83. Anwar M, Iqbal Q, Saleem F. Improper disposal of unused antibiotics: An often-overlooked driver of
- antimicrobial resistance. Expert Rev Anti Infect Ther [Internet]. 2020 Aug;18(8):697-9.
- 755 84. Meyer EL, Golston G, Thomaston S, Thompson M, Rengarajan K, Olinger P. Is your institution
- disposing of culture media containing antibiotics? Applied Biosafety [Internet]. 2017;22(4):164-7.
- 757 85. Grabowski Ł, Gaffke L, Pierzynowska K, Cyske Z, Choszcz M, Węgrzyn G, Węgrzyn A.
- 758 Enrofloxacin-the ruthless killer of eukaryotic cells or the last hope in the fight against bacterial infections?
- 759 International journal of molecular sciences [Internet]. 2022;23(7):3648.

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

86. Ong KH, Khor WC, Quek JY, Low ZX, Arivalan S, Humaidi M, Chua C, Seow KLG, Guo S, Tay MYF, Schlundt J, Ng LC, Aung KT. Occurrence, and antimicrobial resistance traits of escherichia coli from wild birds and rodents in singapore. Int J Environ Res Public Health [Internet]. 2020 Aug 3;17(15):5606. doi: 10.3390/ijerph17155606.87. 87. Lü F, Wang W, Hu T, Duan H, Shao L, Zhang H, He P. Release of airborne antibiotic resistance genes from municipal solid waste transfer stations. Sustainable Environment Research [Internet]. 2022;32(1):28. 88. Straumfors A, Eduard W, Andresen K, Sjaastad AK. Predictors for increased and reduced rat and mouse allergen exposure in laboratory animal facilities. Ann Work Expo Health [Internet]. 2018 Oct 15;62(8):953-65. **Data Availability Statement:** Data is available upon request to the corresponding author. Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

Figure 1.

## **Location of Rodent Facility**




Figure 2.

### **Route of Administration of Antimicrobials**




Figure 3.

"Polymyxin B sulphate + neomycin sulphate or enrofloxacin oral solution and amoxicillin in drinking water, post-irradiation."

"Metronidazole + amoxicillin in chow...amoxicillin + clarithromycin + metronidazole + omeprazole combination in feed for Helicobacter treatment in immunodeficient mice."

"...ampicillin + vancomycin + imipenem + metronidazole + ciprofloxacin in water (to reduce gastrointestinal biome)."

"...vancomycin, ampicillin, neomycin in oral gavage."

medRxiv preprint doi: https://doi.org/10.1101/2023.10.03.23296475; this version posted October 3, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license.

"Trimethoprim sulphonamide + oxytetracycline in food."

"...cephalexin and enrofloxacin."

Figure 4.

# Respondents %

Total=100




Figure 5.

# Methods of Disposal of Antimicrobial Containing Substrate




Figure 6.

## **Sources of Antimicrobials**

